Second,inthePETHEMAstudiesthenumberofpatients withDurieandSalmonStageImyelomaislessthan5% [6] . The 16.9% in this study seems too high and the population appears to be heterogeneous. In all myeloma series there is a proportion of patients with symptomatic stage I MM who require systemic therapy from the beginning. However, one must be certain that the patient has not solitary bone plasmacytomasorsmouldering(asymptomatic)MM(SMM). In the first case, surgery and/or radiation therapy should be the treatment of choice [2] . In case of SMM, no treatment should be administered until evident progressive or symptomatic myelomadevelops [7] .BisphosphonatesarenotrecommendedinSMM [8] .
Third, it is concluded that only 35% of the patients were consideredforHDT/SCT.Consideringthatinthestudypopulation only 40% of the patients were younger that 65 years, the number of patients considered eligible for HDT/SCT seemsreasonable.Whileitistruethatfitpatientsaged65-70 years can be eligible for HDT/SCT, there are patients with MMyoungerthan65yearsthatarenotcandidatesforHDT (i.e.,patientswithsevereco-morbidities,withpoorperformance status or disease complications such as advanced renal failureaswellaspatientswithinitiallyunresponsiveprogressivedisease) [9] .
Fourth,theincreaseduseofnovelagentsintheupfrontas well as in the relapse/refractory settings in the more recent years is an expected finding and should be encouraged [10] . Fortunately,wearealreadyinaneraofimprovementinqualityoflifeandsurvivalofpatientswithMMandwecanforesee an improved long-term outcome for our patients with MM throughanumberofmedicalinterventions:i)thepossibleuse ofatailoredfront-linetherapyforelderlypatientsoptimising the use of MPT (melphalan, prednisone and thalidomide), MPV (melphalan, prednisone and bortezomib) or lenalidomide/dexamethasone according to age, co-morbidities, performance status and disease aggressiveness, ii) using more effectivepre-transplantregimensforyoungerpatientseligible Knaufetal. [1] reportinthecurrentissueofOnkOlOgiethe results of a multicenter survey study performed in order to learnonthechangesinthemanagementofmultiplemyeloma (MM) over time in Germany. For this purpose 386 patients diagnosedina3months-periodfrom35centresinGermany (14%universityhospitals,46%communityhospitalsand40% office-based haematologists) were studied and the results werecomparedwithsimilarsurveysfrom2004and2006.The authors concluded that: i) there were important deviations from international recommended guidelines [2] , ii) a high proportion of patients in Durie and Salmon stage I were treated, iii) a minority of patients was considered for highdosetherapy/stemcelltransplantation(HDT/SCT),andiv)a shift towards the incorporation of novel drugs in the treatmentofMM.Althoughthisstudydemonstratesanimprovement when compared with the results from 2004 and 2006, thereareissuesthatremainofconcerninthegeneralmanagementofpatientswithMM.
First, from this study it seems evident that the baseline evaluation is still suboptimal. Thus, b 2 -microglobulin and serumalbumin,twoeasilyavailableparametersandwhichare requiredforthecurrentInternationalStagingSystemclassification [3] ,weremissinginalmost30%ofthepatients.Even more striking, FISH cytogenetics, the most important prognostic parameter, was studied in only 22% of the patients. Surprisingly(ornotsurprisingly)'proteinuria'wasonlymeasured in 8% of the patients. A minimal baseline evaluation shouldincludethebasichaematologicalpluschemicalvalues (including haemoglobin level plus serum creatinin, calcium, albuminandb 2 -microglobulin)plustotalserumprotein,24-h urineproteinexcretionwithserumandurineelectrophoresis plus serum and urine immunofixation, skeletal survey and bonemarrowaspiratewithFISHanalysiswheneverpossible. Allmyelomatreatingphysiciansshouldkeepinmindthatthe initial disease assessment, response evaluation and monitoringisnotpossiblewithouttheessentialstudiesonserumand urinebasicproteinassays [2, 4, 5] .
groundimmunoglobulinsandthosewithpasthistoryofrecurrentbacterialinfections,particularlypneumococcalpneumonia)appropriateuseoferythropoietinaswellasanadequate managementofrenalfailure [11, 12] . for HDT/SCT resulting in a high pre-and post-transplant complete response rate and this leading to a significantly longer survival, iii) selecting the more appropriate rescue regimensafterrelapseandexploitingtheavailabledrugsina sequential manner according to previous drug exposure, depth and duration of response and previous toxicities, iv) carefulbaselineandresponseevaluationwithanappropriate monitoringthatallowstherecognitionofclinicalprogression ensuringatimelyrescuetherapy,v)adequateprophylaxisand managementoftoxicities,particularlyperipheralneuropathy andthromboticevents,andvi)supportivecarewithoptimal use of biphosphonates, infectious prophylaxis in high-risk patients (renal failure, very high IgG levels with low back-
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